Health AI Register Logo
ProductsPlatformsCompaniesNewsContact
ProductsMindpeak Breast ER/PR

Reviewed 21 Jul 2026

Completeness Strong (64%)

Mindpeak Breast ER/PR

Mindpeak GmbH

Mindpeak Breast ER/PR is intended for in vitro diagnostic use as an aid to the pathologist in the assessment of samples from human breast cancer patients.

Image analysis consists of the detection and classification of IHC stained tumor cells on the whole slide. Tumor cells are classified as not-stained (tumor negative) or stained (tumor positive).

A corresponding ER or PR score is provided as the proportion of the number of tumor positive cells divided by the sum of tumor positive and tumor negative cells.

Supported by 1 paper

Mindpeak Breast ER/PR
Mindpeak Breast ER/PR
Mindpeak Breast ER/PR
Mindpeak Breast ER/PR
Mindpeak Breast ER/PR thumbnail 1
Mindpeak Breast ER/PR thumbnail 2
Mindpeak Breast ER/PR thumbnail 3
Mindpeak Breast ER/PR thumbnail 4

Key Features

  • Cancer detection
  • Cell classification
  • Tissue segmentation

General Information

Product name

Mindpeak Breast ER/PR

Modality

Histopathology

Main task

Scoring (IHC quantification)

Subspeciality

Breast pathology

Organ/Specimen source

Not specified

Disease targeted

Breast cancer

Specimen type

Not specified

Staining

IHC

Stain subtype

ER, PR

Regulatory Information

CE-IVD Certification

Pathway:

In Vitro Diagnostic Directive (IVDD)

Class:

General IVD Devices

Verified by Health AI Register

Scanner Brands Certified for Use (CE-IVD)

Roche, Phillips, 3DHistech, Hamamatsu, Leica

Scanner Models Certified for Use (CE-IVD)

Not specified

Other certifications

Not specified

Evidence & Research

Technical Specifications

Patient population age

Not specified

Input

whole slide image, 0.5 µm/pixel, ER or PR IHC staining

Input format

BIF, MRXS, NDPI, Others, SVS, TIFF

Output

positivity score, tumor cell annotations, classification of tumor positive and tumor negative

Output format

JSON

Integration

Integration via AI marketplace or distribution platform, Integration with IMS (Image Management System)

Deployment

Cloud-based, Hybrid, Locally on dedicated hardware, Locally virtualized (virtual machine, docker)

Trigger for analysis

Automatically, Image upload, On demand, Right after the image acquisition, Triggered by a user through e.g. a button click

Processing time

1 - 10 minutes

Population

Not intended to be used for non-cancer or necrotic tissue, DCIS only lesions, inflammatory breast cancer, breast angiosarcoma or paget disease, Special type carcinoma and rare morphological subtypes of ILC (please contact us for more detailed information), samples from non-adult female patients or male patients of any age, Metastatic lesions, post-therapie samples, cytology specimens

Viewer systems

Digital Lab (Smart in Media), EMPAIA, FullFocus (Paige), Pathflow (Gestalt), PathPresenter, Proscia, Sectra, Telemis, Tribun

Market Presence

On market since

May 2022

AI Platforms

EMPAIA, Gestalt, Paige, PathPresenter, PreciPoint, Proscia, Smart in Media, Telemis, Tribun Health

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Not specified

Based on

Number of analyses

First published: Jul 30, 2025 | Last updated: Jul 21, 2026